436 related articles for article (PubMed ID: 16837456)
41. P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets.
Fälker K; Lange D; Presek P
Thromb Haemost; 2005 May; 93(5):880-8. PubMed ID: 15886804
[TBL] [Abstract][Full Text] [Related]
42. Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets.
Dorsam RT; Tuluc M; Kunapuli SP
J Thromb Haemost; 2004 May; 2(5):804-12. PubMed ID: 15099288
[TBL] [Abstract][Full Text] [Related]
43. PAR4-Mediated PI3K/Akt and RhoA/ROCK Signaling Pathways Are Essential for Thrombin-Induced Morphological Changes in MEG-01 Cells.
Heo Y; Jeon H; Namkung W
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054966
[TBL] [Abstract][Full Text] [Related]
44. Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion.
Huang JS; Dong L; Kozasa T; Le Breton GC
J Biol Chem; 2007 Apr; 282(14):10210-22. PubMed ID: 17298951
[TBL] [Abstract][Full Text] [Related]
45. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation.
Shankar H; Garcia A; Prabhakar J; Kim S; Kunapuli SP
J Thromb Haemost; 2006 Mar; 4(3):638-47. PubMed ID: 16460446
[TBL] [Abstract][Full Text] [Related]
46. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors.
Jin J; Quinton TM; Zhang J; Rittenhouse SE; Kunapuli SP
Blood; 2002 Jan; 99(1):193-8. PubMed ID: 11756171
[TBL] [Abstract][Full Text] [Related]
47. Suboptimal activation of protease-activated receptors enhances alpha2beta1 integrin-mediated platelet adhesion to collagen.
Marjoram RJ; Voss B; Pan Y; Dickeson SK; Zutter MM; Hamm HE; Santoro SA
J Biol Chem; 2009 Dec; 284(50):34640-7. PubMed ID: 19815553
[TBL] [Abstract][Full Text] [Related]
48. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
49. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by α-thrombin.
Arachiche A; Mumaw MM; de la Fuente M; Nieman MT
J Biol Chem; 2013 Nov; 288(45):32553-32562. PubMed ID: 24097976
[TBL] [Abstract][Full Text] [Related]
50. Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation.
Zhang Y; Wang Y; Xiang Y; Lee W; Zhang Y
J Thromb Haemost; 2012 Mar; 10(3):411-8. PubMed ID: 22212092
[TBL] [Abstract][Full Text] [Related]
51. Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance.
Gnanenthiran SR; Pennings GJ; Reddel CJ; Campbell H; Kockx M; Hamilton JR; Chen VM; Kritharides L
Arterioscler Thromb Vasc Biol; 2022 Aug; 42(8):960-972. PubMed ID: 35708029
[TBL] [Abstract][Full Text] [Related]
52. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.
Kirkby NS; Lundberg MH; Chan MV; Vojnovic I; Solomon AB; Emerson M; Mitchell JA; Warner TD
Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15782-7. PubMed ID: 24003163
[TBL] [Abstract][Full Text] [Related]
53. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
54. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
55. PAR1 activation initiates integrin engagement and outside-in signalling in megakaryoblastic CHRF-288 cells.
Cichowski K; Orsini MJ; Brass LF
Biochim Biophys Acta; 1999 Jul; 1450(3):265-76. PubMed ID: 10395938
[TBL] [Abstract][Full Text] [Related]
56. Characterization of the distinct mechanism of agonist-induced canine platelet activation.
Chaudhary PK; Kim S
J Vet Sci; 2019 Jan; 20(1):10-15. PubMed ID: 30541187
[TBL] [Abstract][Full Text] [Related]
57. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
[TBL] [Abstract][Full Text] [Related]
58. Thrombopoietin complements G(i)- but not G(q)-dependent pathways for integrin {alpha}(IIb){beta}(3) activation and platelet aggregation.
Campus F; Lova P; Bertoni A; Sinigaglia F; Balduini C; Torti M
J Biol Chem; 2005 Jul; 280(26):24386-95. PubMed ID: 15863506
[TBL] [Abstract][Full Text] [Related]
59. The role of PAR4 in thrombin-induced thromboxane production in human platelets.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Teng CM
Thromb Haemost; 2003 Aug; 90(2):299-308. PubMed ID: 12888878
[TBL] [Abstract][Full Text] [Related]
60. Critical role of ADP interaction with P2Y12 receptor in the maintenance of alpha(IIb)beta3 activation: association with Rap1B activation.
Kamae T; Shiraga M; Kashiwagi H; Kato H; Tadokoro S; Kurata Y; Tomiyama Y; Kanakura Y
J Thromb Haemost; 2006 Jun; 4(6):1379-87. PubMed ID: 16706985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
